BNGO BIONANO GENOMICS INC

Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, is scheduled to participate in a fireside chat on Wednesday, February 16th, 2022 at 2:30 pm ET. BTIG hosted events are intended for prospective and existing BTIG clients. To listen to the live event, please contact your BTIG representative with interest.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit ,  or .

CONTACTS

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Amy Conrad

Juniper Point

+1 (858) 366-3243

Media Relations:

Michael Sullivan

Seismic

+1 (503) 799-7520



EN
09/02/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE

Bionano to Report Fourth Quarter and Full Year 2025 Financial Results ...

Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Webcast Link: Participants may access a live webcast o...

 PRESS RELEASE

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadt...

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automatio...

 PRESS RELEASE

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Uti...

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how these conditions, which include developmental delay, intellectual disability, neuromuscular disorders, reproductive disorders, birth defects and other so-called rare diseases, present unique challenges to t...

 PRESS RELEASE

11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding...

11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing Applications with Optical Genome Mapping (OGM). The session revealed how OGM can offer a new standard for detecting and characterizing structural variants (SVs) across cancer, including its unprecedented resolution in rare and heterogeneous c...

 PRESS RELEASE

9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering ...

9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molec...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch